Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Minor: ALKS 2680 · Narcolepsy Type 1 Trial sites expanded: 42 → 66 locations Alkermes, Inc.Phase 3 NCT07455383
  2. Minor: GB-0895 Adjunctive Therapy in Adults and · Severe Uncontrolled Asthma (SOLAIRIA-2) Trial sites expanded: 158 → 166 locations Generate BiomedicinesPhase 3 NCT07359846
  3. Minor: Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD) Trial sites expanded: 50 → 56 locations Airway Therapeutics, Inc.Phase 2/3 NCT06897839
  4. Minor: EYE201/MK-8748 · Macular Degeneration (MK-8748-002) Trial sites expanded: 132 → 148 locations EyeBiotech Ltd.Phase 2/3 NCT07440225
  5. Minor: New Formulation of Oral Cladribine Compared With Placebo · Generalized Myasthenia Gravis (MyClad) Trial sites expanded: 153 → 159 locations Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyPhase 3 NCT06463587
  6. Minor: Canvuparatide Compared With Placebo · Hypoparathyroidism Trial sites expanded: 22 → 28 locations MBX BiosciencesPhase 3 NCT07699471
  7. Minor: Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) Trial sites expanded: 168 → 174 locations Novartis PharmaceuticalsPhase 3 NCT07357727
  8. Minor: Xywav Expanded Dosing vs Placebo · Narcolepsy or IH Trial sites expanded: 15 → 27 locations Jazz PharmaceuticalsPhase 3 NCT07625280
  9. Minor: ALKS 2680 · Narcolepsy Type 1 (Brilliance NT1 - 304) Trial sites expanded: 20 → 53 locations Alkermes, Inc.Phase 3 NCT07540897
  10. Minor: Outcomes of Pemvidutide in MASH Trial sites expanded: 9 → 62 locations Altimmune, Inc.Phase 3 NCT07795164
  11. Minor: Efimosfermin Compared With Placebo · Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) Trial sites expanded: 35 → 39 locations GlaxoSmithKlinePhase 3 NCT07704892
  12. Minor: BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer Trial sites expanded: 52 → 77 locations BioNTech SEPhase 3 NCT07365995
  13. Minor: Fenfluramine Hydrochloride in Rett Syndrome Trial sites expanded: 40 → 46 locations UCB BIOSCIENCES, Inc.Phase 3 NCT07503444
  14. Minor: Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections · Multiple Myeloma Trial sites expanded: 65 → 68 locations TakedaPhase 3 NCT06980480
  15. Minor: Efimosfermin Alfa Compared With Placebo · Alcohol-related Liver Disease (ALD) Trial sites expanded: 13 → 17 locations GlaxoSmithKlinePhase 2 NCT07791043
  16. Minor: Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy · HER2-positive Breast Cancer Trial sites expanded: 53 → 60 locations Jazz PharmaceuticalsPhase 2 NCT07102381
  17. Minor: PIPE 791 · Idiopathic Pulmonary Fibrosis Trial sites expanded: 108 → 111 locations Contineum TherapeuticsPhase 2 NCT07284459
  18. Minor: EP-104GI · Eosinophilic Esophagitis (EoE) Trial sites expanded: 23 → 33 locations Eupraxia Pharmaceuticals Inc.Phase 1/2 NCT05608681
  19. Minor: Afimkibart · Rheumatoid Arthritis Trial sites expanded: 10 → 17 locations Hoffmann-La RochePhase 2 NCT07620392
  20. Minor: LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy Trial sites expanded: 1 → 22 locations Lexeo TherapeuticsPhase 2 NCT07721025
  21. Minor: EPI-326 in EGFR-mutant NSCLC and HNSCC Trial sites expanded: 6 → 12 locations EpiBiologicsPhase 1 NCT07462377
  22. Minor: Methylene Blue Photodynamic Therapy · Deep Tissue Abscesses Enrollment increased: 120 → 150 participants University of RochesterPhase 2 NCT06052956
  23. Minor: S241656 in Selected RAS/MAPK Mutation- Positive Malignancies Enrollment increased: 554 → 623 participants Institut de Recherches Internationales ServierPhase 1/2 NCT05786924
  24. Minor: VIR-5500 (AMX-500) in Prostate Cancer Trial sites expanded: 26 → 30 locations Astellas Pharma Global Development, Inc.Phase 1 NCT05997615
  25. Minor: CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007) Trial sites expanded: 4 → 15 locations Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 1 NCT07300085